Summit Therapeutics (SMMT) Receivables - Other (2017 - 2025)

Summit Therapeutics (SMMT) posted quarterly Receivables - Other of $12000.0 for Q1 2025, down 86.67% on a QoQ basis from $90000.0 in Q3 2024.

Summit Therapeutics (SMMT) Receivables - Other (2017 - 2025) Analysis & Trends

Summit Therapeutics (SMMT) has reported Receivables - Other for 7 consecutive years, with $12000.0 the latest figure, recorded in Q1 2025.

Quarterly Receivables - Other changed N/A year-over-year to $12000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $12000.0 (changed N/A YoY) and the FY2021 annual result came in at $574000.0, changed N/A from the prior year.
Receivables - Other declined to $12000.0 in Q1 2025 per SMMT's latest filing, from $90000.0 in the prior quarter.
Over the last five years, Receivables - Other for SMMT reached as high as $1.1 million in Q2 2022 and fell as low as $12000.0 in Q1 2025.
A 4-year average of $397833.3 and a median of $322500.0 in 2022 frame the typical range for Receivables - Other.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Summit Therapeutics	11.62 Bn	11.03 Bn	-

Download Data